Parkinson disease is the second-most common neurodegenerative disorder that affects 2–3%
of the population≥ 65 years of age. Neuronal loss in the substantia nigra, which causes …

We present a clinimetric assessment of the Movement Disorder Society (MDS)‐sponsored
revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS). The MDS‐UDPRS …

This document presents the Movement Disorder Society Clinical Diagnostic Criteria for
Parkinson's disease (PD). The Movement Disorder Society PD Criteria are intended for use in …

A preceding article described the clinical features of Parkinson's disease dementia (PD‐D)
and proposed clinical diagnostic criteria for “probable” and “possible” PD‐D. The main focus …

Background A therapy that slows disease progression is the major unmet need in Parkinson's
disease. Methods In this double-blind trial, we examined the possibility that rasagiline has …

Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria,
published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for …

Dementia has been increasingly more recognized to be a common feature in patients with
Parkinson's disease (PD), especially in old age. Specific criteria for the clinical diagnosis of …

Background Neurostimulation of the subthalamic nucleus reduces levodopa-related motor
complications in advanced Parkinson's disease. We compared this treatment plus medication …

Background: A consensus conference on multiple system atrophy (MSA) in 1998 established
criteria for diagnosis that have been accepted widely. Since then, clinical, laboratory, …

The Movement Disorder Society Task Force for Rating Scales for Parkinson's disease (PD)
prepared a critique of the Hoehn and Yahr scale (HY). Strengths of the HY scale include its …